To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
75276617ALE1002 - Menin ComboA Phase 1b Study of JNJ-75276617 in Combination with AML-Directed Therapies: A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations | |
---|---|
Local Project Reference: | 148364 |
Principal Investigator: | Dr Jenny O'Nions |
Drug Class/ Treatrment: | JNJ-75276617 (Menin-KMT2A Inhibitor) |
Patient Population: | Acute Myeloid Leukemia (AML) with KMT2A or NPM1 Alterations |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
CCS1477-02An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies | |
---|---|
Local Project Reference: | 121140 |
Principal Investigator: | Dr Jenny O'Nions |
Drug Class/ Treatrment: | CCS1477 (P300/CBP Inhibitor) |
Patient Population: | Advanced Haematological Malignancies |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
EP0042-101A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate theSafety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies. | |
---|---|
Local Project Reference: | 134892 |
Principal Investigator: | Dr Jenny O'Nions |
Drug Class/ Treatrment: | FLT3 inhibitor & Aurora Kinase Inhibitor: EP0042 Monotherapy and Combination - Oral administration |
Patient Population: | Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndromes (MDS) |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
PROMISEInvestigation into the combination of PLX2853 with Ruxolitinib in patients with intermediate-2 or high risk myelofibrosis not receiving an adequate response with ruxolitinib alone. | |
---|---|
Local Project Reference: | 136172 |
Principal Investigator: | Dr. Jenny O'Nion |
Drug Class/ Treatrment: | PLX2853 (BET Inhibitor) + Ruxolitinib (JAK Inhibitor) |
Patient Population: | Intermediate or High-Risk Myelofibrosis |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
CL1-65487-003Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multicentre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl2 inhibitor combined with azacitidine in adult patients with previously untreated acute myeloid leukemia not eligible for intensive treatment | |
---|---|
Local Project Reference: | 136715 |
Principal Investigator: | Dr Jenny O'Nions |
Drug Class/ Treatrment: | S65487 (BCL2 Inhibitor) Combination S65487 and Azacitidine. Receiving 7 days Azacitidne and weekly S65487 infusions through the vein every 28 days. |
Patient Population: | Acute Myeloid Leukaemia (AML) |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
AUTO-1AUTO1 in relapsed or refractory B-ALL : AN OPEN-LABEL, MULTI-CENTRE, PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF AUTO1, A CAR T CELL TREATMENT TARGETING CD19, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA | |
---|---|
Local Project Reference: | 127550 |
Principal Investigator: | Dr. Claire Roddie |
Drug Class/ Treatrment: | AUTO1 (CAR T-Cell Therapy Targeting CD19) |
Patient Population: | RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
FEDORAFEDORA : A phase II study to evaluate the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis | |
---|---|
Local Project Reference: | 146196 |
Principal Investigator: | Dr Donal McLornan |
Drug Class/ Treatrment: | Fedratanib (JAK2 Inhibitor) + Ropeginterferon Alfa-2b (Pegylated Interferon) |
Patient Population: | Myelofibrosis |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
ELECTRAA Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ELA026 in Adults and Adolescents with Secondary Hemophagocytic Lymphohistiocytosis (sHLH) | |
---|---|
Local Project Reference: | 145018 |
Principal Investigator: | Dr Satyen Gohil |
Drug Class/ Treatrment: | ELA026 (IgG1 SIRP-Directed Monoclonal Antibody) |
Patient Population: | Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Adults and Adolescents (≥12 years at the time of HLH diagnosis) |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
KCAT191/1KCAT19: Allogeneic T cells expressing T cell receptor-KDEL and the chimeric antigen receptor CAT19 for the treatment of advanced CD19+ malignancies | |
---|---|
Local Project Reference: | 126800 |
Principal Investigator: | Dr Maeve O’Reilly |
Drug Class/ Treatrment: | KCAT19 T-Cells |
Patient Population: | Advanced CD19+ Malignancies Acute B-Cell Leukaemia |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |